[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ligand Pharm (LGND)

Ligand Pharm (LGND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,634,189
  • Shares Outstanding, K 20,038
  • Annual Sales, $ 268,090 K
  • Annual Income, $ 124,450 K
  • EBIT $ 74 M
  • EBITDA $ 104 M
  • 60-Month Beta 1.14
  • Price/Sales 17.08
  • Price/Cash Flow 29.10
  • Price/Book 4.42

Options Overview Details

View History
  • Implied Volatility 48.50% (+1.03%)
  • Historical Volatility 38.92%
  • IV Percentile 89%
  • IV Rank 44.19%
  • IV High 73.14% on 04/13/26
  • IV Low 28.98% on 08/08/25
  • Expected Move (DTE 18) 5.10 (2.14%)
  • Put/Call Vol Ratio 0.65
  • Today's Volume 56
  • Volume Avg (30-Day) 76
  • Put/Call OI Ratio 0.34
  • Today's Open Interest 1,080
  • Open Int (30-Day) 1,100
  • Expected Range 232.74 to 242.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $1.01
  • Number of Estimates 3
  • High Estimate $1.37
  • Low Estimate $0.63
  • Prior Year $-2.21
  • Growth Rate Est. (year over year) +145.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
188.67 +25.18%
on 03/30/26
247.38 -4.53%
on 04/27/26
+40.69 (+20.82%)
since 03/27/26
3-Month
178.72 +32.15%
on 02/26/26
247.38 -4.53%
on 04/27/26
+40.68 (+20.81%)
since 01/27/26
52-Week
98.89 +138.82%
on 05/30/25
247.38 -4.53%
on 04/27/26
+128.10 (+118.53%)
since 04/25/25

Most Recent Stories

More News
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator 

Transaction expands Ligand’s royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand’s long-term compounding growth, adding a complementary...

LGND : 234.08 (+1.22%)
XOMA : 41.42 (+9.29%)
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator

Transaction expands Ligand’s royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand’s long-term compounding growth, adding a complementary...

XOMA : 41.42 (+9.29%)
LGND : 234.08 (+1.22%)
XOMAP : 25.21 (-3.50%)
XOMAO : 25.20 (-0.90%)
Ligand to Report First Quarter 2026 Financial Results on May 7, 2026

JUPITER, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026....

LGND : 234.08 (+1.22%)
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS

FILSPARI is the first and only approved medicine for this rare kidney disorder and leading cause of kidney failure Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI JUPITER,...

TVTX : 41.13 (+1.56%)
LGND : 234.08 (+1.22%)
Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team

JUPITER, Fla., March 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed two leading healthcare investors, Peter Renehan, MD, and Lee Brown...

LGND : 234.08 (+1.22%)
Ligand to Participate in March Investor Conferences

JUPITER, Fla., March 04, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor...

LGND : 234.08 (+1.22%)
Ligand: Q4 Earnings Snapshot

Ligand: Q4 Earnings Snapshot

LGND : 234.08 (+1.22%)
Ligand Reports Fourth Quarter and Full Year 2025 Financial Results

Robust financial performance driven by full year 2025 royalty revenue growth of  48% Reiterating 2026 financial guidance of $245-$285 million in revenues and adjusted earnings per diluted share...

LGND : 234.08 (+1.22%)
Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

JUPITER, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2025 financial results on Thursday,...

LGND : 234.08 (+1.22%)
Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

JUPITER, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will...

LGND : 234.08 (+1.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ligand, being a biotechnology company, focuses on developing/acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure. Ligand's Captisol formulation technology has allowed it to enter into several licensing deals and generate royalties. Captisol is a well validated...

See More

Key Turning Points

3rd Resistance Point 240.43
2nd Resistance Point 236.09
1st Resistance Point 233.68
Last Price 233.65
1st Support Level 226.93
2nd Support Level 222.59
3rd Support Level 220.18

See More

52-Week High 247.38
Last Price 233.65
Fibonacci 61.8% 190.66
Fibonacci 50% 173.14
Fibonacci 38.2% 155.61
52-Week Low 98.89

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.